EVENT BROCHURE

BIOLOGICS MANUFACTURING DACH 2027

Biologics Manufacturing DACH 2027

17–18 February 2027

CO-LOCATED EVENTS

CGT MANUFACTURING DACH 2027

OFFICIAL EVENT BROCHURE

https://infohub.imapac.com/biologics-manufacturing-dach-2027

Table of Contents

What is new in 2027?	3
Agenda at a Glance	4
Agenda	5
Meet the Speakers	11
Sponsors & Media Partner	14
Our Past Partners	15
DACH Series Past Partners	18
Expected Audience Snapshot	19
Targeted Attendees List	20
Sponsorship Packages	22
Sponsorship Opportunities	23
Testimonials	24
Add to Calendar	27
About IMAPAC	28

EVENT HIGHLIGHTS

250+ ATTENDEES

80+ COMPANIES

20+ EXPERT SPEAKERS

DATE & VENUE

17-18 February 2027

Munich
Germany

CO-LOCATED EVENTS

CGT MANUFACTURING DACH 2027

About the Event

WHAT IS NEW IN 2027?

BIOLOGICS MANUFACTURING DACH 2027

This year introduces the DACH Bioprocessing Excellence Awards, recognising manufacturing innovation, operational excellence, and leadership across cell & gene therapy, biologics, and oligos & peptides.

The programme brings cell & gene therapy, biologics, and oligos & peptides together in one agenda, reflecting the shift toward multi-platform and hybrid manufacturing models.

There is a stronger emphasis on late-stage CMC, tech transfer, GMP readiness, and cost-of-goods, aligning discussions with real-world commercialisation challenges.

New sessions highlight digital and automated manufacturing, including digital twins, PAT, real-time release testing, and closed-system operations.

The agenda places greater focus on patient-centric and decentralized CGT models, covering autologous manufacturing, point-of-care production, and chain of identity.

Discussions are tailored to DACH-specific operational and sustainability priorities, including facility design, supplier risk, energy efficiency, and regional regulatory expectations.

WHAT TO EXPECT

250+
Decision Makers

20+
Expert Speakers

80+
Companies Represented

FEATURED TESTIMONIAL

"I had the pleasure of collaborating with the IMAPAC team during the Irish leg of the Biologics World event in February 2026. The organisers were exceptionally receptive and helpful, ensuring a seamless experience throughout the planning, exhibition logistics, partnering sessions, and sponsor visibility. Their proactive approach in connecting us with potential partners significantly enhanced our ROI. We are already exploring future opportunities to work with the IMAPAC team."

Terry Gray · Field Marketing Manager · Merck

Agenda at a Glance

DAY 1 | 17 FEBRUARY 2027	DAY 2 | 18 FEBRUARY 2027
The Future of Biologics Manufacturing: Building Scalable, Resilient and Intelligent Operations	Advancing CMC for Next-Generation Biologics
NETWORKING BREAK	
Next-Generation Upstream Manufacturing	Novel Approaches to Biosafety Testing
LUNCH	
Optimising Downstream Throughput	AI, Digitalisation & Smart Biomanufacturing
NETWORKING BREAK	
Industry Roundtables: Solving Tomorrow's Manufacturing Challenges Today	Building Flexible Facilities for a Multi-Modality Future
END OF CONFERENCE DAY 1	END OF CONFERENCE

BIOLOGICS MANUFACTURING DACH 2027

Day 1

17 February 2027

08:00 **Registration & Coffee**

08:50

Chairman's Welcome Address

Nicoletta Loggia
Chief Technology Officer, Orchard Therapeutics, Switzerland

The Future of Biologics Manufacturing

09:00

PANEL DISCUSSION

The Biologics Factory of 2030: AI, Digital Twins and the Future of Manufacturing Excellence

- Where AI is delivering value today
- Digital twins versus reality
- PAT and real-time process understanding
- Building GMP-compliant digital manufacturing environments

PANELLISTS

Dr Ulrich Rümenapp
Senior Biotech Program Lead, Bayer, Germany

Bettina Knapp
Head of Digital Operations Drug Substance, Boehringer Ingelheim Pharma, Germany

09:30 **Reserved for Solution Provider**

10:00

Commercial Manufacturability by Design: Why Scale-Up Success Starts During Development

- Integrating manufacturability into early development
- Bridging process development and commercial manufacturing
- Embedding QbD and process understanding from day one
- Avoiding costly scale-up and tech transfer failures

10:30 **Networking Break**

Day 1

17 February 2027

Next-Generation Upstream Manufacturing

11:10

The Intensification Paradox: When More Upstream Productivity Creates Downstream Problems

- Are upstream teams optimising the wrong KPIs?
- When increased titres overwhelm downstream capacity
- Facility implications of intensified processes
- Balancing yield, quality and throughput

11:40

Reserved for Solution Provider

12:10

AI-Driven Upstream Development: Can Digital Twins Predict Scale-Up Success?

- Current state of digital twin deployment
- Predictive cell culture modelling
- AI-assisted process development
- Separating hype from practical value

13:00

Lunch

Optimising Downstream Throughput

14:00

Maximising Yield Without Compromising Quality in Commercial Biologics Manufacturing

- Reducing product loss across the manufacturing process
- Balancing yield and product quality
- Process robustness at commercial scale
- Cost-of-goods optimisation

Day 1

17 February 2027

14:30 — **Reserved for Solution Provider**

15:00

From Process Understanding to Product Quality: Linking CPPs, CQAs and Downstream Performance

- Process understanding strategies
- Managing critical quality attributes
- Data-driven validation
- Regulatory expectations for commercial manufacturing

15:30 — **Networking Break**

16:00

ROUNDTABLE DISCUSSION

1. Integrating AI into GMP Environments Without Compromising Compliance (TBC)
   Alessio Epifanio — Director, Environmental Health, Safety & Sustainability, J&J Innovative Medicine, Italy
2. Bridging the Gap Between Process Development and Commercial Manufacturing (TBC)
   Charlotte Nicole Bigum — Head of QC and AS&T, BioNtech, Germany
3. Biomanufacturing Without Silos: Connecting Development, Manufacturing, Quality and Supply Chain
4. Building Supply Chain Resilience in an Era of Geopolitical Uncertainty
5. Beyond the Contract: What Does a True Manufacturing Partnership Look Like?

17:00 — **Cocktail Reception**

17:15 — **END OF CONFERENCE DAY 1**

BIOLOGICS MANUFACTURING DACH 2027

Day 2

18 February 2027

08:00 **Registration & Coffee**

08:50 **Chairman's Welcome Address**

Advancing CMC for Next-Generation Biologics

09:00

Building Adaptable CMC Strategies for Complex Biologics

- Technology transfer as a strategic CMC activity
- Balancing transfer speed, flexibility, and risk control
- Addressing product complexity in the design of technology transfer strategies

Melanie Dannemeyer
Associate Director Tech Transfer, AstraZeneca, Sweden

09:30 **Reserved for Solution Provider**

10:00

Driving Efficiency in Quality Operations through LEAN thinking

- Flow Efficiency vs. Resource Efficiency
- Examples from QC, Deviation Handling and Documentation Management
- LEAN Leadership Behaviors

Frank Seibel
Quality Site Head, Vice President, Roche, Germany

10:30 **Networking Break**

Novel Approaches to Biosafety Testing

Day 2

18 February 2027

11:10

Building a Risk-Based Biosafety Testing Strategy for Complex

- Defining biosafety-testing requirements based on product modality, process risk, and development stage
- Integrating rapid and compendial methods without compromising data integrity or regulatory acceptability
- Establishing clear decision pathways for atypical results, investigations, and batch-impact assessment
- Aligning development, quality, manufacturing, and external testing partners around a coherent testing strategy

Baerbel Grossmann
Associate Director Global Regulatory Affairs CMC Biologics, Sanofi, Germany

11:40

Reserved for Solution Provider

12:10

From Cell Bank to Commercial Supply: Strengthening Contamination Control Across the Biologics Lifecycle

- Building viral-safety strategy into cell-bank qualification
- Identifying contamination risks across the manufacturing process
- Using monitoring and trend analysis to strengthen control
- Protecting supply continuity during investigations and scale-up

13:00

Lunch

AI, Digitalisation & Smart Biomanufacturing

14:00

PANEL DISCUSSION

Smart Manufacturing for a Sustainable Future (TBC)

- AI and digital tools for greener manufacturing operations
- Improving resource efficiency through connected manufacturing
- Building resilient and sustainable production networks
- Measuring sustainability through real-time operational insights

Alessio Epifanio
Director, Environmental Health, Safety & Sustainability, J&J Innovative Medicine, Italy

Roberto Corazza
Operational Excellence, Digital and Strategy Director, J&J Innovative Medicine, Italy

Day 2

18 February 2027

14:30 — **Reserved for Solution Provider**

15:00

How Smart Planning enables Commercial Readiness

- Path towards commercial readiness for global supply chains
- Challenges and pitfalls for E2E Planning
- AI solutions enabling smart planning

Maximilian Abress
Senior Director Global Supply Chain, BioNTech, Germany

Karin Keppeler
Associate Director E2E Supply Chain, BioNTech, Germany

15:30 — **Networking Break**

Building Flexible Facilities for a Multi-Modality Future

16:00

Lessons Learned from Internal and External Technology Transfers: Navigating Unexpected Challenges (TBC)

Charlotte Nicole Bigum
Head of QC and AS&T, BioNtech, Germany

16:30

Designing Facilities for Process Intensification and Perfusion Manufacturing

- Facility implications of intensified processing
- Supporting perfusion at commercial scale
- Infrastructure requirements for higher productivity
- Balancing flexibility and capacity

17:00 — **Closing Remarks**

17:15 — **END OF CONFERENCE DAY 1**

MEET THE SPEAKERS

BIOLOGICS MANUFACTURING DACH 2027



Baerbel Grossmann
Associate Director Global Regulatory Affairs CMC Biologics
Sanofi
GERMANY



Bettina Knapp
Head of Digital Operations Drug Substance
Boehringer Ingelheim Pharma
GERMANY



Alessio Epifanio
Director, Environmental Health, Safety & Sustainability
J&J Innovative Medicine
ITALY



Melanie Dannemeyer
Associate Director Tech Transfer
AstraZeneca
SWEDEN



Frank Seibel
Quality Site Head, Vice President
Roche
GERMANY



Maximilian Abress
Senior Director Global Supply Chain
BioNTech
GERMANY



Karin Keppeler
Associate Director E2E Supply Chain
BioNTech
GERMANY



Roberto Corazza
Operational Excellence, Digital and Strategy Director
J&J Innovative Medicine
ITALY

BIOLOGICS MANUFACTURING DACH 2027



Charlotte Nicole Bigum
Head of QC and AS&T
BioNtech
GERMANY



Dr. Ulrich Rümenapp
Senior Biotech Program Lead
Bayer
GERMANY



Luca Febbraio
Head of Supply Chain Management
Catalym
GERMANY



Cornelia Thieme
Global Head of Pharmaceutical Science, MSAT
Galderman
SWITZERLAND



Marian Wiegand
TherVacB Program Manager
Institute of Virology at Helmholtz Munich
GERMANY

CGT MANUFACTURING DACH 2027



CHAIRMAN

Nicoletta Loggia
Chief Technology Officer
Orchard Therapeutics
SWITZERLAND



Marion Hitchcock
Managing Director Gene & Cell Therapies Incubator
Bayer
GERMANY



Chris Baldwin
Vice President, Manufacturing and Supply
Resolution Therapeutics
UK



Gulbengu Kuzgun Yuksel
Network Head of Quality Cell & Gene Therapy
Roche
SWITZERLAND



Bart Van Waeyenberge
EMEA Head of CAR T Operations
Johnson & Johnson
BELGIUM



Parag Kumthekar
Lead Gene Therapy Downstream Team
UCB
BELGIUM



Prof. Nicki Panoskaltsis
Professor and Chair of Personalised Therapeutics
Trinity College Dublin
IRELAND



Dr John Bridgeman
Chief Scientific Officer
ImmunoKey
UK

Sponsors & Media Partner

GOLD

clean cells
SOLUTION FOR BIOLOGICS

BioReliance®
Contract Testing Services


Our Past Partners




Our Past Partners (cont.)



Our Past Partners (cont.)



DACH Series Past Partners



Expected Audience Snapshot

80%
BIOPHARMA & BIG PHARMA

20%
SERVICE & SOLUTION PROVIDERS

BY PROFILE

Emerging / Mid-size Biotech	53%
Large Pharma & Biopharma Manufacturers	41%
CDMOs (Lonza, Evotec, Rentschler)	4%
Academia & Research Institutes	1%
Regulatory / Service & Consulting	1%


BY JOB TITLE

CMC / Pharmaceutical Development	36%
Process Development, MSAT & Tech Transfer	23%
Manufacturing & Operations	11%
Other / General Management (unmatched titles)	8%
Executive Leadership (C-Suite/Founders)	6%
Quality & Compliance	5%
Supply Chain & External Manufacturing	5%
R&D / Scientific	3%
Regulatory Affairs	3%

DECISION MAKERS

Decision Makers	99%
Others	1%

BY GEOGRAPHY



Targeted Attendees List

Companies and senior roles represented across the selected event(s)

BIOLOGICS MANUFACTURING DACH 2027

JOB TITLE	COMPANY	COUNTRY
Job Title	Company	Country
Director, Analytical Development	Valneva	Austria
Associate Director, Manufacturing	MorphoSys	Germany
Head of External Manufacturing	Formycon	Germany
Proposal Manager	Rentschler Biopharma	Germany
Chief Technology Officer	QurAlis	United States
Head of CMC	Boehringer Ingelheim	Germany
Director, Biopharmaceutical Development	Lonza	Switzerland
Senior Director, MSAT	Novartis	Switzerland
Director, Manufacturing Science & Technology	Ribbon Biolabs	Austria
Chief Technical Operations Officer	T-Knife	Switzerland
Director CMC Proteins	BioNTech	Germany
Head of External Manufacturing	Ferring Pharmaceuticals	Switzerland
Head of CMC	invIOs	Austria
Senior Director, MSAT	Valneva	Austria
Head of External Manufacturing	Boehringer Ingelheim	Germany
Head of CMC	MorphoSys	Germany
Head of RNA Therapeutics	invIOs	Austria
Head of Biology	Ikarovec Ltd	United Kingdom
Director, Analytical Development	Valneva	Austria
Associate Director, Manufacturing	MorphoSys	Germany

Targeted Attendees List (cont.)

BIOLOGICS MANUFACTURING DACH 2027

JOB TITLE	COMPANY	COUNTRY
Head of External Manufacturing	Formycon	Germany
Proposal Manager	Rentschler Biopharma	Germany
Chief Technology Officer	QurAlis	United States
Head of CMC	Boehringer Ingelheim	Germany
Director, Biopharmaceutical Development	Lonza	Switzerland
Senior Director, MSAT	Novartis	Switzerland
Director, Manufacturing Science & Technology	Ribbon Biolabs	Austria
Chief Technical Operations Officer	T-Knife	Switzerland
Director CMC Proteins	BioNTech	Germany
Head of External Manufacturing	Ferring Pharmaceuticals	Switzerland
Head of CMC	invIOs	Austria
Senior Director, MSAT	Valneva	Austria
Head of External Manufacturing	Boehringer Ingelheim	Germany
Head of CMC	MorphoSys	Germany
Head of RNA Therapeutics	invIOs	Austria
Head of Biology	Ikarovec Ltd	United Kingdom

VIEW THE FULL ATTENDEE LIST →

Sponsorship Opportunities

Sponsorship Packages

DIAMOND

PACKAGE INCLUDES

- Full-day workshop for 30 pax: room, lunch, 2 refreshment breaks, coffee / tea
- Keynote solo presentation: 20 min + 5 min Q&A
- 25-minute end-user client case study
- 12 sqm exhibition space (4×3m booth + banner)
- 1 speaker pass; 7 guest passes; 2 exhibitor passes
- 10 onsite 1:1 meetings
- Lead retrieval

PLATINUM

PACKAGE INCLUDES

- Half-day workshop for 30 pax: room, 1 refreshment break, coffee / tea
- Prime-billing solo presentation: 20 min + 5 min Q&A
- 25-minute end-user client case study
- 12 sqm exhibition space (4×3m booth + banner)
- 1 speaker pass; 7 guest passes; 2 exhibitor passes
- 10 onsite 1:1 meetings
- Lead retrieval

GOLD

PACKAGE INCLUDES

- Prime-billing solo presentation: 20 min + 5 min Q&A
- 9 sqm exhibition space (3×3m booth + banner)
- 1 speaker pass; 5 guest passes; 2 exhibitor passes
- 10 onsite 1:1 meetings
- Lead retrieval

SILVER (ENHANCED)

PACKAGE INCLUDES

- Solo presentation: 20 min + 5 min Q&A
- 6 sqm exhibition space (3×2m booth + banner)
- 1 speaker pass; 3 guest passes; 2 exhibitor passes
- 5 onsite 1:1 meetings
- Lead retrieval

SILVER

PACKAGE INCLUDES

- Solo presentation: 10 min + 5 min Q&A
- 6 sqm exhibition space (3×2m booth + tabletop display)
- 1 speaker pass; 2 guest passes; 2 exhibitor passes
- 5 onsite 1:1 meetings
- Lead retrieval

BRONZE

PACKAGE INCLUDES

- Solo presentation: 10 min + 5 min Q&A
- 6 sqm exhibition space (3×2m booth)
- 1 speaker pass; 2 guest passes
- Lead retrieval

EXHIBITION + 10 MEETINGS

PACKAGE INCLUDES

- 6 sqm exhibition space (3×2m booth + banner)
- 1 guest pass; 2 exhibition passes
- 10 onsite 1:1 meetings
- Lead retrieval

EXHIBITION + 5 MEETINGS

PACKAGE INCLUDES

- 6 sqm exhibition space (3×2m booth + banner)
- 1 guest pass; 2 exhibition passes
- 5 onsite 1:1 meetings
- Lead retrieval

EXHIBITION

PACKAGE INCLUDES

- 6 sqm exhibition space (3×2m booth + banner)
- 1 guest pass; 2 exhibition passes
- Lead retrieval

Sponsorship Opportunities

BIOLOGICS MANUFACTURING DACH 2027

Who Should Sponsor?

- Bioprocess Equipment Providers
- Engineering And Facility Design Firms
- Cell Culture Media Providers
- Filters And Chromatography Columns
- Cell Line Providers
- Automation And Process Analytical Technology Firms
- Contract Development and Manufacturing Organisations
- Fill & Finish And Drug Delivery Solutions

Why Sponsor

SPONSORSHIP BENEFITS

- Thought Leadership Speaking
- Panel Participation
- Solution Showcases
- Engagement and Visibility Opportunities
- Branding and Digital Visibility
- Exclusive Networking

TESTIMONIALS

The Biologics and CGT Manufacturing DACH conference 2026 was very well planned and coordinated. It provided high-quality talks for staying up-to-date in our industry and I specifically enjoyed the time for networking.



Dr Heiner Apeler
VP Head of Biologics Development
Bayer
GERMANY

Thanks for the invite to speak at the event. It was a really enjoyable meeting and a great opportunity to present our work to the community. Identifying key partners for ImmunoKey's development plan is a critical aspect of getting our therapies to patients; the CGT and Biologics Manufacturing DACH meeting offered us the opportunity to engage with key CDMOs who can help us achieve this goal.



John Bridgeman
CSO
Immunokey
UK

Just back from an incredible time at the Biologics Manufacturing DACH congress! I have to be honest - as someone in Procurement, some of the deep-dives into Cell & Gene and biologics development were definitely above my scientific capabilities! However, the exchange of knowledge was fantastic, and it was a privilege to learn from such brilliant minds. A true highlight was the fantastic collaboration with Christopher Pawlak (PhD) . I had the privilege of co-hosting a round table with him focused on the impact of tariffs in the biopharma world. Christoph, thank you for the partnership - it was a truly dynamic discussion! 🤝 One of my biggest takeaways is that we have officially entered the era of "The Great Reshoring". We are moving past the days when drug manufacturing decisions were purely scientific; they are now deeply geopolitical. As we discussed in our round table, we can no longer just react to change. We have to treat scenario planning like a muscle that we train constantly to design for volatility. The event really hit home how much our world is changing - from the incredible progress in biologics manufacturing to the AI evolution. I'm excited to see how we can implement these insights to build resilience and benefit BMS biologics manufacturing. Back to my desk, I will start with socializing the learnings with my colleagues. A huge thank you to Drishti G. for the flawless organization and to Noel Murphy for approving the trip and supporting this critical learning opportunity!



Dennis Stelljes
Associate Director, Strategic Sourcing & Procurement, Biologics External Manufacturing
BMS
SWITZERLAND

TESTIMONIALS (cont.)

Really well organised conference with great attendees and high engagement - I was delighted to have taken the time to attend and really enjoyed sharing my thoughts on Accelerating Biologics Pipeline and ensuing discussion. Thank you to all organisers and facilitators



Dr Andrew Kelly
Director, Manufacturing Technology
BMS
IRELAND

A fantastic deep dive into the DACH region's CGT landscape. This conference made one thing clear: efficacy is proven, but industrialization is the new frontier. To truly move the needle, we must look beyond the lab and focus on scaling automation, streamlining supply chains, and tackling COGS. The diversity of voices - from large corporations, to tech suppliers and academic pioneers - provided a 360-degree view of the manufacturing challenges we must solve together.



Dr Thomas Villiger
Professor of Bioprocess Technology
University of Applied Sciences and Arts Northwestern Switzerland FHNW
SWITZERLAND

Thanks for the invite. The conference was really excellent, due to the caliber and engagement of the attendees.



Brian O'Connor
VP Global Quality
Orchard Therapeutics
UK

Thanks for putting this together! I enjoyed the discussions, atmosphere and engagement of participants. Great to be there!



Alvaro Avivar-Valderas
Associate Director - Cell Therapy Technology & Product Engine
Takeda
SPAIN

TESTIMONIALS (cont.)

I thoroughly enjoyed attending the CGT Manufacturing DACH 2026 by IMAPAC. The program featured exceptionally industry-relevant talks that provided deep insights into the current landscape. Beyond the sessions, the networking opportunities were top-tier, thanks to the high caliber of participants.



Steffen Schulze
Strategic Analytics & Business Analytics Lead
Roche
SWITZERLAND

I had the pleasure of collaborating with the IMAPAC team during the Irish leg of the Biologics World event in February 2026. The organisers were exceptionally receptive and helpful, ensuring a seamless experience throughout the planning, exhibition logistics, partnering sessions, and sponsor visibility. Their proactive approach in connecting us with potential partners significantly enhanced our ROI. We are already exploring future opportunities to work with the IMAPAC team.

Terry Gray
Field Marketing Manager
Merck

Thank you for your email and organising this wonderful event. It was a pleasure to participate. Congratulations on organising this event. It was a wonderful opportunity to present our work and to collaborate with others in the area. Looking forward to your next event



Warren Roche
Senior Statistical Expert
Sanofi
IRELAND

Thank you, it was a pleasure meeting you, and your enthusiasm made it an engaging and positive event. I hope we have opportunity to connect again in the future.



Michael Inglis
Head of Manufacturing Sciences, Analytical Technologies
Chiesi Farmaceutici Global Rare Disease
IRELAND

Well done on a very informative and successful event.



Shada Warreth
Global Partnerships Implementation Senior Manager
NIBRT
IRELAND

MARK YOUR CALENDAR

Save the Date

17–18 FEB 2027 — Munich

Biologics Manufacturing DACH 2027

ALL IMAPAC EVENTS

Explore Our Full Event Calendar

Discover upcoming IMAPAC biopharmaceutical conferences, summits, and exhibitions across Europe and worldwide. →

OR ADD THIS EVENT TO YOUR CALENDAR

Google Calendar
One-click add to Gmail →

Outlook Calendar
Add to Microsoft Outlook →

Scan to Register

Open camera, point at code, instant registration access.

Or click the QR to open registration directly.

A VARIETY OF PRODUCTS TO CATER TO GLOBAL BIOPHARMACEUTICAL INDUSTRY'S MARKET INTELLIGENCE AND BUSINESS CONNECTIONS NEEDS.

01 B2B EVENTS

Thought-leadership, industry knowledge-sharing and quality networking are at the core of IMAPAC's B2B events.

Create an engaging experience for your audiences, explore our B2B Events Solutions.

02 360 MARKETING SOLUTIONS

Expand your reach and influence! Be it with customized events, digital marketing solutions, content creation or thought-leadership.

Tap into our global audience spanning the sub-sectors and regions shaping the biopharmaceutical industry.

03 DASHBOARDS

A quick-view analytics tool to power your decisions. Access region or country-specific data to uncover pipeline information, product focus.

Customize the dashboard based on your needs. Drill down to the data you need using custom views.

04 CUSTOM RESEARCH

Based on your objectives and budget, you can customize a package to one that best meets your intelligence needs. This allows you to maximize your ROI without spending on items that are not in line with your strategies.

With access to a database of 60,000+ life science professionals. We conduct research with a highly-qualified audience.

05 REPORTS

Discover in-depth market information of the growing biopharmaceutical sector.

Learn More →

HELPING THE GLOBAL BIOPHARMACEUTICAL INDUSTRY

Generate Tangible Growth

IMAPAC is the one-stop shop of market intelligence and business connections for the global biopharmaceutical industry. We help companies expand their influence, make data driven decisions through our industry intelligence, and link up with other biopharmaceutical professionals to exchange knowledge and engage in quality networking. At the core of IMAPAC is our mission to help biopharmaceutical businesses globally generate tangible growth. At the same time, our heart lies in giving back to society. We empower the next generation by equipping underprivileged children with an education.

WEBSITE
imapac.com

EMAIL
info@imapac.com

IMAPAC PTE LTD
36 Robinson Road, #02-01
Singapore 068877
+65 6983 6140

IMAPAC UK LTD
77 Farringdon Road, Farringdon
London EC1M 3JU, United Kingdom
+44 161 552 8507

CONNECT WITH US

LINKEDIN
@imapac

X
@imapac

FACEBOOK
ImapacPteLtd